bio-ConneKt Wound Matrix
Commercial- Indications
- Acute wounds, Chronic wounds, Trauma wounds, Surgical wounds, Burn wounds
Company intelligence / Profile preview
MLM Biologics’ lead product, bio-ConneKt® Wound Matrix—a collagen-based wound dressing—has received FDA clearance and unique CMS reimbursement code. It has demonstrated clinical utility in managing various acute and chronic skin breaches. The company recently secured U.S. Army funding to develop an anti-infective device for battlefield use, leveraging its proprietary technology with anti-inflammatory and antimicrobial components. Clinical results are positive enough to support commercial launch and ongoing expansion into new indications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MLM Biologics.